mDCF + Avelumab in Resectable Esophago-gastric Adenocarcinoma (EGA)

Conditions:   Gastric Adenocarcinoma;   Esophageal Adenocarcinoma
Intervention:   Drug: mDCF + Avelumab
Sponsor:   McGill University Health Center
Not yet recruiting - verified September 2017

http://ift.tt/2hiqoni